Phase 3A trial in 1687 people with severe asthma controlled on mepolizumab or benralizumab: switching to twice-yearly depemokimab failed non-inferiority for exacerbations (0.57 vs 0.49/year; rate ratio 1.16, 95% CI 0.98-1.38).
RCTn = 1,687
Chupp et al. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE)